ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas
- 1 February 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 178 (2) , 181-188
Abstract
Objective: Platinum-based chemotherapy (PBC) is the most effective cytotoxic treatment for advanced adrenocortical carcinoma (ACC). Excision repair cross complementing group 1 (ERCC1) plays a critical role in the repair of platinum-induced DNA damage. Two studies investigating the role of ERCC1 immunostaining as a predictive marker for the response to PBC in ACC had reported conflicting results. Both studies used the ERCC1-antibody clone 8F1 that later turned out to be not specific. The aim of this study was to evaluate the predictive role of ERCC1 with the new specific antibody in a larger series of ACC. Design and Methods: 146 ACC patients with available FFPE slides were investigated. All patients underwent PBC (median cycles=6), including cisplatin (n=131) or carboplatin (n=15), in most cases combined with etoposide (n=144), doxorubicin (n=131) and mitotane (n=131). Immunostaining was performed with the novel ERCC1-antibody clone 4F9. The relationship between ERCC1 expression and clinico-pathological parameters, as well as best objective response to therapy and progression-free survival (PFS) during PBC was evaluated. Results: High ERCC1 expression was observed in 66% of ACC samples. During PBC, 43 patients experienced objective response (29.5%), 49 stable disease (33.6%), 8 mixed response (5.5%) and 46 progressive disease (31,5%) without any relationship with the ERCC1 immunostaining. No significant correlation was also found between ERCC1 expression and progression-free survival (median 6.5 vs 6 months, P=0.33, HR=1.23, 95%CI=0.82-2.0). Conclusion: ERCC1 expression is not directly associated with sensitivity to PBC in ACC. Thus, other predictive biomarkers are required to support treatment decisions in patients with ACC.Keywords
This publication has 31 references indexed in Scilit:
- Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumoursBritish Journal of Cancer, 2013
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathologyBMC Biotechnology, 2012
- Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinomaEndocrine-Related Cancer, 2010
- Validation of ERCC1-XPF Immunodetection – LetterCancer Research, 2010
- Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human TissueCancer Research, 2009
- Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinomaCancer, 2009
- ERCC1 and Non–Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapyAnnals of Oncology, 2007
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006